home LATEST ONCOPRESCRIBE UPDATES Breast-Conserving Surgery with or without Irradiation in Early Breast CancerFirst-Line Time Limited Venetoclax Combinations in Chronic Lymphocytic LeukemiaInterrupting Endocrine Therapy to Attempt Pregnancy after Breast CancerLONSURF® Plus Bevacizumab Improves Overall Survival in Advanced Refractory Colorectal CancerHER2DX Genomic Assay Predicts Pathological Response in Early Stage HER2-Positive Breast CancerTreatment of Oligometastatic Non-Small Cell Lung Cancer: An ASTRO/ESTRO Clinical Practice GuidelineORSERDU® for ESR-1 Mutated Advanced Breast CancerBRUKINSA® for First Line Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma SHOW MORE FDAApprovals Meeting Updates Hem/OncUpdates Molecular Tidbits NEW REGIMENS ADDEDResearch RegimensTIBSOVO® - for Acute Myeloid Leukemia Single Agent LUMAKRAS® - for Non Small Cell Lung CancerKEYTRUDA® - for Malignant Melanoma TECENTRIQ® and ABRAXANE® - for Breast CancerKEYTRUDA® plus INLYTA® - for Renal CancerPARAPLATIN® and VEPESID® with TECENTRIQ® - for Small Cell Lung CancerIMFINZI® Consolidation - for Locally Advanced Non Small Cell Lung CancerCABOMETYX® - for Renal Cancer Curbside ConsultationLung Cancer Special IssueImmuno-OncologyPrecision OncologyCOVID-19 Associated Coagulopathy: Diagnosis and ManagementTTP, HUS and aHUS: Different diseases – Different treatmentsHER2 Testing in Breast Cancer American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused UpdateDual Inhibition Improves Outcomes for Patients with BRAF-Mutated Colorectal TumorsFDA Approves ENDARI®, A New Treatment for Sickle Cell DiseaseSHOW MORE